Cargando…

Clinical features of patients with type 2 diabetes with and without Covid-19: A case control study (CoViDiab I)

AIMS: To evaluate whether subjects with diabetes hospitalized for Coronavirus disease-19 (Covid-19) represent a subgroup of patients with high-risk clinical features compared to patients with diabetes without Covid-19. METHODS: In this case-control study 79 patients with type 2 diabetes out of 354 a...

Descripción completa

Detalles Bibliográficos
Autores principales: Maddaloni, Ernesto, D'Onofrio, Luca, Alessandri, Francesco, Mignogna, Carmen, Leto, Gaetano, Coraggio, Lucia, Sterpetti, Sara, Pascarella, Giuseppe, Mezzaroma, Ivano, Lichtner, Miriam, Pozzilli, Paolo, Agrò, Felice Eugenio, Rocco, Monica, Pugliese, Francesco, Mastroianni, Claudio Maria, Buzzetti, Raffaella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505069/
https://www.ncbi.nlm.nih.gov/pubmed/32971157
http://dx.doi.org/10.1016/j.diabres.2020.108454
_version_ 1783584744214102016
author Maddaloni, Ernesto
D'Onofrio, Luca
Alessandri, Francesco
Mignogna, Carmen
Leto, Gaetano
Coraggio, Lucia
Sterpetti, Sara
Pascarella, Giuseppe
Mezzaroma, Ivano
Lichtner, Miriam
Pozzilli, Paolo
Agrò, Felice Eugenio
Rocco, Monica
Pugliese, Francesco
Mastroianni, Claudio Maria
Buzzetti, Raffaella
author_facet Maddaloni, Ernesto
D'Onofrio, Luca
Alessandri, Francesco
Mignogna, Carmen
Leto, Gaetano
Coraggio, Lucia
Sterpetti, Sara
Pascarella, Giuseppe
Mezzaroma, Ivano
Lichtner, Miriam
Pozzilli, Paolo
Agrò, Felice Eugenio
Rocco, Monica
Pugliese, Francesco
Mastroianni, Claudio Maria
Buzzetti, Raffaella
author_sort Maddaloni, Ernesto
collection PubMed
description AIMS: To evaluate whether subjects with diabetes hospitalized for Coronavirus disease-19 (Covid-19) represent a subgroup of patients with high-risk clinical features compared to patients with diabetes without Covid-19. METHODS: In this case-control study 79 patients with type 2 diabetes out of 354 adults hospitalized for Covid-19 and 158 controls with type 2 diabetes but without Covid-19, matched for age and gender, were enrolled. Medical history and concomitant therapies were retrieved from medical charts and compared between cases and controls, controlling for confounders. RESULTS: Fully-adjusted multivariate logistic regression model showed that previous CVD history did not differ between patients with and without Covid-19 (odds ratio 1.40, 95% confidence interval [CI]: 0.59–3.32, p = 0.45). A higher prevalence of chronic obstructive pulmonary disease (COPD) (OR 3.72, 95%CI: 1.42–9.72, p = 0.007) and of chronic kidney disease (CKD) (OR 3.08, 95%CI: 1.18–8.06, p = 0.022) and a lower prevalence of ever smokers (OR 0.30, 95%CI: 0.13–0.67, p = 0.003), of users of lipid lowering agents (OR 0.26, 95%CI: 0.12–0.54, p < 0.001), and of anti-hypertensive drugs (OR 0.39, 95%CI: 0.16–0.93, p = 0.033) were found among cases. CONCLUSIONS: CVD prevalence does not differ between people with diabetes with and without Covid-19 requiring hospitalization. An increased prevalence of COPD and of CKD in Covid-19 patients with type 2 diabetes is suggested. These findings aid to clarify the relationship between underlying conditions and SARS-CoV-2 infection in the high-risk group of patients with diabetes.
format Online
Article
Text
id pubmed-7505069
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-75050692020-09-23 Clinical features of patients with type 2 diabetes with and without Covid-19: A case control study (CoViDiab I) Maddaloni, Ernesto D'Onofrio, Luca Alessandri, Francesco Mignogna, Carmen Leto, Gaetano Coraggio, Lucia Sterpetti, Sara Pascarella, Giuseppe Mezzaroma, Ivano Lichtner, Miriam Pozzilli, Paolo Agrò, Felice Eugenio Rocco, Monica Pugliese, Francesco Mastroianni, Claudio Maria Buzzetti, Raffaella Diabetes Res Clin Pract Article AIMS: To evaluate whether subjects with diabetes hospitalized for Coronavirus disease-19 (Covid-19) represent a subgroup of patients with high-risk clinical features compared to patients with diabetes without Covid-19. METHODS: In this case-control study 79 patients with type 2 diabetes out of 354 adults hospitalized for Covid-19 and 158 controls with type 2 diabetes but without Covid-19, matched for age and gender, were enrolled. Medical history and concomitant therapies were retrieved from medical charts and compared between cases and controls, controlling for confounders. RESULTS: Fully-adjusted multivariate logistic regression model showed that previous CVD history did not differ between patients with and without Covid-19 (odds ratio 1.40, 95% confidence interval [CI]: 0.59–3.32, p = 0.45). A higher prevalence of chronic obstructive pulmonary disease (COPD) (OR 3.72, 95%CI: 1.42–9.72, p = 0.007) and of chronic kidney disease (CKD) (OR 3.08, 95%CI: 1.18–8.06, p = 0.022) and a lower prevalence of ever smokers (OR 0.30, 95%CI: 0.13–0.67, p = 0.003), of users of lipid lowering agents (OR 0.26, 95%CI: 0.12–0.54, p < 0.001), and of anti-hypertensive drugs (OR 0.39, 95%CI: 0.16–0.93, p = 0.033) were found among cases. CONCLUSIONS: CVD prevalence does not differ between people with diabetes with and without Covid-19 requiring hospitalization. An increased prevalence of COPD and of CKD in Covid-19 patients with type 2 diabetes is suggested. These findings aid to clarify the relationship between underlying conditions and SARS-CoV-2 infection in the high-risk group of patients with diabetes. Elsevier B.V. 2020-11 2020-09-21 /pmc/articles/PMC7505069/ /pubmed/32971157 http://dx.doi.org/10.1016/j.diabres.2020.108454 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Maddaloni, Ernesto
D'Onofrio, Luca
Alessandri, Francesco
Mignogna, Carmen
Leto, Gaetano
Coraggio, Lucia
Sterpetti, Sara
Pascarella, Giuseppe
Mezzaroma, Ivano
Lichtner, Miriam
Pozzilli, Paolo
Agrò, Felice Eugenio
Rocco, Monica
Pugliese, Francesco
Mastroianni, Claudio Maria
Buzzetti, Raffaella
Clinical features of patients with type 2 diabetes with and without Covid-19: A case control study (CoViDiab I)
title Clinical features of patients with type 2 diabetes with and without Covid-19: A case control study (CoViDiab I)
title_full Clinical features of patients with type 2 diabetes with and without Covid-19: A case control study (CoViDiab I)
title_fullStr Clinical features of patients with type 2 diabetes with and without Covid-19: A case control study (CoViDiab I)
title_full_unstemmed Clinical features of patients with type 2 diabetes with and without Covid-19: A case control study (CoViDiab I)
title_short Clinical features of patients with type 2 diabetes with and without Covid-19: A case control study (CoViDiab I)
title_sort clinical features of patients with type 2 diabetes with and without covid-19: a case control study (covidiab i)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505069/
https://www.ncbi.nlm.nih.gov/pubmed/32971157
http://dx.doi.org/10.1016/j.diabres.2020.108454
work_keys_str_mv AT maddaloniernesto clinicalfeaturesofpatientswithtype2diabeteswithandwithoutcovid19acasecontrolstudycovidiabi
AT donofrioluca clinicalfeaturesofpatientswithtype2diabeteswithandwithoutcovid19acasecontrolstudycovidiabi
AT alessandrifrancesco clinicalfeaturesofpatientswithtype2diabeteswithandwithoutcovid19acasecontrolstudycovidiabi
AT mignognacarmen clinicalfeaturesofpatientswithtype2diabeteswithandwithoutcovid19acasecontrolstudycovidiabi
AT letogaetano clinicalfeaturesofpatientswithtype2diabeteswithandwithoutcovid19acasecontrolstudycovidiabi
AT coraggiolucia clinicalfeaturesofpatientswithtype2diabeteswithandwithoutcovid19acasecontrolstudycovidiabi
AT sterpettisara clinicalfeaturesofpatientswithtype2diabeteswithandwithoutcovid19acasecontrolstudycovidiabi
AT pascarellagiuseppe clinicalfeaturesofpatientswithtype2diabeteswithandwithoutcovid19acasecontrolstudycovidiabi
AT mezzaromaivano clinicalfeaturesofpatientswithtype2diabeteswithandwithoutcovid19acasecontrolstudycovidiabi
AT lichtnermiriam clinicalfeaturesofpatientswithtype2diabeteswithandwithoutcovid19acasecontrolstudycovidiabi
AT pozzillipaolo clinicalfeaturesofpatientswithtype2diabeteswithandwithoutcovid19acasecontrolstudycovidiabi
AT agrofeliceeugenio clinicalfeaturesofpatientswithtype2diabeteswithandwithoutcovid19acasecontrolstudycovidiabi
AT roccomonica clinicalfeaturesofpatientswithtype2diabeteswithandwithoutcovid19acasecontrolstudycovidiabi
AT pugliesefrancesco clinicalfeaturesofpatientswithtype2diabeteswithandwithoutcovid19acasecontrolstudycovidiabi
AT mastroianniclaudiomaria clinicalfeaturesofpatientswithtype2diabeteswithandwithoutcovid19acasecontrolstudycovidiabi
AT buzzettiraffaella clinicalfeaturesofpatientswithtype2diabeteswithandwithoutcovid19acasecontrolstudycovidiabi
AT clinicalfeaturesofpatientswithtype2diabeteswithandwithoutcovid19acasecontrolstudycovidiabi